435
Views
2
CrossRef citations to date
0
Altmetric
Journal Club

Study design and clinical evidence in mRCC

Can we save axitinib as a first-line therapy?

, , &
Pages 486-488 | Received 17 Jan 2014, Accepted 09 Feb 2014, Published online: 20 Feb 2014

Figures & data

Figure 1. Forest plot of cumulative HR for PFS in patients treated with axitinib or sorafenib as first targeted agent.

Figure 1. Forest plot of cumulative HR for PFS in patients treated with axitinib or sorafenib as first targeted agent.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.